Tetracycline
Achromycin, Helidac, Pylera, Tetracyn, Tetrex (tetracycline) is a small molecule pharmaceutical. Tetracycline was first approved as Achromycin on 1982-01-01. It is used to treat acne vulgaris, bacterial eye infections, bacterial infections, bartonella infections, and borrelia infections amongst others in the USA.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
infections | D007239 |
respiratory tract diseases | D012140 |
eye diseases | D005128 |
urogenital diseases | D000091642 |
skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Achromycin (generic drugs available since 1982-01-01, discontinued: Actisite, Bristacycline, Cyclopar, Panmycin, Retet, Robitet, Sumycin, Tetrachel, Tetracyn, Tetramed, Tetrex, Topicycline)
CombinationsPylera (generic drugs available since 1982-01-01, discontinued: Achromycin, Helidac, Tetracyn)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bismuth subcitrate potassium
+
Metronidazole
+
Tetracycline hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PYLERA | AbbVie | N-050786 RX | 2006-09-28 | 1 products, RLD, RS |
Bismuth subsalicylate
+
Metronidazole
+
Tetracycline hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
HELIDAC | Casper Pharma | N-050719 DISCN | 1996-08-15 | 1 products, RLD |
Hide discontinued
Hydrocortisone
+
Tetracycline hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ACHROMYCIN | Lederle Laboratories | N-050272 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Procaine hydrochloride
+
Tetracycline hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ACHROMYCIN | Lederle Laboratories | N-050276 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Tetracycline hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ACHROMYCIN V | Avet Lifesciences | N-050278 RX | 1982-01-01 | 2 products, RLD |
Show 6 discontinued
Tetracycline phosphate complex
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TETREX | Bristol Myers Squibb | N-050212 DISCN | 1982-01-01 | 2 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
helidac therapy | ANDA | 2020-06-17 |
pylera | New Drug Application | 2021-12-15 |
tetracycline hydrochloride | ANDA | 2023-05-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
acne vulgaris | EFO_0003894 | D000152 | L70 |
bacterial eye infections | — | D015818 | — |
bacterial infections | — | D001424 | A49 |
bartonella infections | EFO_0007166 | D001474 | A44 |
borrelia infections | EFO_1000842 | D001899 | — |
bronchitis | — | D001991 | J40 |
campylobacter infections | EFO_0007190 | D002169 | — |
chancroid | — | D002602 | A57 |
chlamydia infections | EFO_0007205 | D002690 | A74.9 |
cholera | — | D002771 | A00 |
Show 10 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A01: Stomatological preparations
— A01A: Stomatological preparations
— A01AB: Antiinfectives and antiseptics for local oral treatment
— A01AB13: Tetracycline
— A02: Drugs for acid related disorders
— A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
— A02BD: Combinations for eradication of helicobacter pylori
— A02BD02: Lansoprazole, tetracycline and metronidazole
— A02BD08: Bismuth subcitrate, tetracycline and metronidazole
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06A: Antibiotics for topical use
— D06AA: Tetracycline and derivatives, topical antibiotics
— D06AA04: Tetracycline
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01A: Tetracycline antibiotics
— J01AA: Tetracyclines
— J01AA07: Tetracycline
— J01R: Combinations of antibacterials
— J01RA: Combinations of antibacterials
— J01RA08: Tetracycline and oleandomycin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA09: Tetracycline
— S02: Otologicals
— S02A: Antiinfective drugs, otologic
— S02AA: Antiinfectives
— S02AA08: Tetracycline
— S03: Ophthalmological and otological preparations
— S03A: Antiinfectives, ophthalmologic and otologic
— S03AA: Antiinfectives
— S03AA02: Tetracycline
Clinical
Clinical Trials
84 clinical trials
View more details

Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Infections | D007239 | EFO_0000544 | 1 | — | 1 | 25 | 5 | 32 | |
Gastritis | D005756 | EFO_0000217 | K29.7 | 1 | — | — | 2 | 1 | 4 |
Helicobacter infections | D016481 | EFO_1000961 | — | — | 1 | 2 | 1 | 4 | |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | — | — | 2 | — | 3 |
Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | 2 | — | 2 |
Helicobacter pylori | D016480 | NCBITaxon_210 | B96.81 | — | — | — | 1 | 1 | 2 |
Trichiasis | D058457 | HP_0001128 | — | — | — | 1 | — | 1 | |
Peptic ulcer | D010437 | HP_0004398 | K27 | — | — | — | 1 | — | 1 |
Dyspepsia | D004415 | EFO_0008533 | K30 | — | — | — | 1 | — | 1 |
Dysbiosis | D064806 | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Bacterial vaginosis | D016585 | EFO_0003932 | — | — | 2 | — | — | 2 | |
Trachoma | D014141 | A71 | — | — | 1 | — | — | 1 | |
Vulvovaginal candidiasis | D002181 | EFO_0007543 | B37.3 | — | — | 1 | — | — | 1 |
Candidiasis | D002177 | B37 | — | — | 1 | — | — | 1 | |
Burns | D002056 | T30.0 | — | 1 | 1 | — | — | 1 | |
Periodontitis | D010518 | EFO_0000649 | K05.3 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | C85.9 | — | 2 | — | — | — | 2 | |
Lung neoplasms | D008175 | C34.90 | — | 1 | — | — | — | 1 | |
Exanthema | D005076 | R21 | — | 1 | — | — | — | 1 | |
Non-hodgkin lymphoma | D008228 | C85.9 | — | 1 | — | — | — | 1 | |
Chronic periodontitis | D055113 | EFO_0006343 | K05.3 | — | 1 | — | — | — | 1 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
Post-lyme disease syndrome | D000077342 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Malignant pleural effusion | D016066 | J91.0 | 1 | — | — | — | — | 1 | |
Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
Chalazion | D017043 | EFO_0007363 | H00.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Gingival recession | D005889 | K06.0 | — | — | — | — | 2 | 2 | |
Neoplasms | D009369 | C80 | — | — | — | — | 1 | 1 | |
Head and neck neoplasms | D006258 | — | — | — | — | 1 | 1 | ||
Dry eye syndromes | D015352 | H04.12 | — | — | — | — | 1 | 1 | |
Paronychia | D010304 | EFO_0007421 | L03.0 | — | — | — | — | 1 | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
Covid-19 | D000086382 | U07.1 | — | — | — | — | 1 | 1 | |
Pneumothorax | D011030 | J93.11 | — | — | — | — | 1 | 1 | |
Wound infection | D014946 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | TETRACYCLINE |
INN | tetracycline |
Description | Tetracycline is a broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria. It has a role as an antimicrobial agent, an antibacterial drug, an antiprotozoal drug, a protein synthesis inhibitor and an Escherichia coli metabolite. It is a tertiary alpha-hydroxy ketone and a member of tetracyclines. It is a conjugate acid of a tetracycline(1-) and a tetracycline zwitterion. |
Classification | Small molecule |
Drug class | antibiotics (tetracycline derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12 |
Identifiers
PDB | — |
CAS-ID | 60-54-8 |
RxCUI | 10395 |
ChEMBL ID | CHEMBL1440 |
ChEBI ID | 27902 |
PubChem CID | 54675776 |
DrugBank | DB00759 |
UNII ID | F8VB5M810T (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 128,754 documents
View more details
Safety
Black-box Warning
Black-box warning for: Helidac therapy, Pylera
Adverse Events
Top Adverse Reactions

Mock data
Subscribe for the real data
Subscribe for the real data
35,815 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more